GlassScriptPhysician profile
Taylor J Holve
NPI 1477756815
$14,849.44
in general payments reported to CMS, 2019-2025
25 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Adult Congenital Heart Disease provider received nationally (typical 2025 total: $272).
See the full distribution for Adult Congenital Heart Disease
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $270 · 2021: $61.43 · 2022: $275 · 2023: $107 · 2024: $3,338 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,104 · Food and Beverage: $1,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,104.15 |
| Food and Beverage | $1,814.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $9,202.04 | 2019-2025 | |
| Medtronic, INC. | $3,217.04 | 2021-2025 | Micra, Selectsecure |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $259.06 | 2019-2025 | Lifevest |
| Abbott Laboratories | $222.08 | 2022-2024 | |
| Boston Scientific Corporation | $194.85 | 2021-2025 | Watchman Flx, Watchman Access System |
| Amgen INC. | $159.18 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $158.22 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $156.86 | 2019-2023 | Farxiga |
| Pfizer INC. | $153.52 | 2019-2025 | |
| Lundbeck LLC | $152.90 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $128.37 | 2019-2020 | |
| Medtronic Vascular, INC. | $127.45 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $126.42 | 2019-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $120.56 | 2019-2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.47 | 2019-2025 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $67.07 | 2019-2025 | |
| Amarin Pharma, INC. | $55.28 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $45.46 | 2019 | |
| Ge Healthcare | $45.18 | 2019 | |
| Irhythm Technologies, INC. | $41.69 | 2019 | |
| Bridgebio Pharma, INC. | $36.83 | 2025 | Attruby |
| Portola Pharmaceuticals, LLC | $26.46 | 2019 | |
| Atricure, INC. | $16.17 | 2019 | |
| Esperion Therapeutics, INC. | $15.10 | 2025 | Nexletol |
| Biosense Webster, INC. | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Holve listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.